ACCENDRA HEALTH INC/VA/ Earnings Per Share Disclosure
Note 13—Net (Loss) Income per Common Share
The following summarizes the calculation of net (loss) income per common share attributable to common shareholders for the years ended December 31, 2025, 2024 and 2023:
(in thousands, except per share data) | |||||||||
Years Ended December 31, | | 2025 | | 2024 | | 2023 | |||
(Loss) income from continuing operations, net of tax | $ | (102,682) | $ | (350,735) | $ | 8,905 | |||
Loss from discontinued operations, net of tax |
| (997,960) |
| (11,951) |
| (50,206) | |||
Net loss | $ | (1,100,642) | $ | (362,686) | $ | (41,301) | |||
Weighted average shares outstanding - basic |
| 76,897 |
| 76,741 |
| 75,785 | |||
Dilutive shares |
| — |
| — |
| 1,582 | |||
Weighted average shares outstanding - diluted |
| 76,897 |
| 76,741 |
| 77,367 | |||
Basic loss per common share: |
| |
| |
| | |||
(Loss) income from continuing operations, net of tax | $ | (1.34) | $ | (4.57) | $ | 0.12 | |||
Loss from discontinued operations, net of tax |
| (12.97) |
| (0.16) |
| (0.66) | |||
Net loss | $ | (14.31) | $ | (4.73) | $ | (0.54) | |||
Diluted loss per common share: |
| |
| |
| | |||
(Loss) income from continuing operations, net of tax | $ | (1.34) | $ | (4.57) | $ | 0.12 | |||
Loss from discontinued operations, net of tax | $ | (12.97) | $ | (0.16) | $ | (0.65) | |||
Net loss | $ | (14.31) | $ | (4.73) | $ | (0.53) | |||
Share-based awards for the years ended December 31, 2025 and 2024, of approximately 2.2 million and 1.5 million shares were excluded from the calculation of net loss per diluted common share as the effect would be anti-dilutive. In accordance with ASC 260, dilutive shares are included in computing the diluted loss per common share from discontinued operations, net of tax and net loss per diluted common share for the year ended December 31, 2023 even though they were anti-dilutive, as the control number (income from continuing operations, net of tax) was in an income position.
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Feb 20, 2026 | Showing above |
| 2024 | Feb 28, 2025 | |
| 2023 | Feb 20, 2024 | |
| 2022 | Feb 28, 2023 | |
| 2017 | Feb 23, 2018 | |
About Earnings Per Share Disclosures
The earnings per share disclosure breaks down the calculation from net income to both basic and diluted EPS, revealing the full impact of a company's capital structure on per-share economics. The reconciliation between basic and diluted share counts exposes how many stock options, RSUs, convertible securities, and warrants are potentially dilutive to existing shareholders.
Key signals: a widening gap between basic and diluted shares indicates growing dilution from equity compensation or convertible instruments. Anti-dilutive securities excluded from the diluted calculation deserve attention — they represent latent dilution that will materialize if the stock price rises. Watch for the effect of share buybacks on per-share metrics: EPS growth driven primarily by repurchases rather than income growth signals weakening fundamentals. Compare year-over-year changes in the diluted share count against equity compensation expense to assess whether management is effectively managing dilution.